Table 3.
Logistic regression model to identify potential predictors of risk of MRONJ in cancer patients.
| Covariate | OR (CI 95%) | p-Value |
|---|---|---|
| Age | 0.99 (0.96–1.03) | 0.755 |
| Sex (male) | 1.60 (0.81–3.16) | 0.171 |
| Lung cancer | 0.59 (0.16–2.17) | 0.430 |
| Breast cancer | 0.65 (0.34–1.24) | 0.189 |
| Multiple myeloma | 1.68 (0.68–4.16) | 0.261 |
| Prostate cancer | 1.73 (0.79–3.80) | 0.170 |
| Number of administered doses of zoledronic acid/denosumab | 1.03 (1.01–1.05) | 0.008 |
| Chemotherapy | 0.35 (0.17–0.71) | 0.003 |
| Novel molecules | 1.07 (0.52–2.19) | 0.855 |
| Hormonal therapy | 0.65 (0.34–1.24) | 0.189 |
Legend: OR = Odds Ratio; CI = Confidence Interval. Statistically significant p-values are reported in bold.